Market Cap
$11.7M
GTBP
GT Biopharma, Inc.
$6.03 ▼ -2.74%
Prev close $6.20Market cap$11.7M
12-mo target$75.00 (+1143.8%)
High Impact Filing (7/10)4 New Institutional Positions Biotech & Drug Discovery
Snapshot
The big-picture read on GTBP right now — valuation, ownership and activity at a glance.
Cap Size
Nano Cap
Inst. Holders
24 funds
Inst. Value
$644.4K
Inst. Activity
4 buys / 2 sells
SEC Reports
6
Press Releases
1
Price chart 30d +2030.7%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 23, 2026 listing_status
Sep 15, 2026 SEC Listing Status: GTBP — Normal (was Deficient)
GT Biopharma, Inc. - Common Stock | Nasdaq Financial Status Indicator D → N
GT Biopharma entered into a securities purchase agreement to sell up to 41,778 shares of Series M 10% Convertible Prefer
8-K — Impact 7/10
GT Biopharma filed a Certificate of Amendment to effect a 1-for-25 reverse stock split and reduce authorized shares from
8-K — Impact 4/10
GT Biopharma reported Q2 2026 EPS of -$0.11, missing consensus of -$0.08 by 37.5%, with no revenue. Cash runway of $5.1M
PRESS-RELEASE — Impact 5/10
Jun 30, 2026 Inst.
Integrated Wealth Concepts LLC — DOUBLED
40,012 shares ($19.6K)
Jun 30, 2026 Inst.
Mar 2, 2026 Press OSAIC HOLDINGS, INC. — ADD
38,500 shares ($18.9K)
GT Biopharma reported its 2025 financial results, showing reduced R&D and operating losses but a sharply higher net loss
Impact 5/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Dec 2, 2024 | Roth MKM | INITIATE | Buy | 52% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Aug 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jul 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Price targets
Where 1 covering analysts think GTBP trades over the next 12 months.
$75.00 +1143.8% upside Strong Buy
Current$6.03 Low$75.00 Median$75.00 High$75.00 1 analysts
$75.00$75.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
6 SEC filing reports analyzed · 0 bullish, 4 bearish, 0 mixed, 2 neutral · avg impact 5.7/10.Plus 1 press releases.
BEARISH8-K7/10
GT Biopharma entered into a securities purchase agreement to sell up to 41,778 shares of Series M 10
Sep 15, 2026
NEUTRAL8-K4/10
GT Biopharma filed a Certificate of Amendment to effect a 1-for-25 reverse stock split and reduce au
Sep 3, 2026
BEARISHPRESS-RELEASE5/10
GT Biopharma reported Q2 2026 EPS of -$0.11, missing consensus of -$0.08 by 37.5%, with no revenue.
Aug 14, 2026
BEARISH8-K7/10
GT Biopharma received a Nasdaq notice granting an additional 180-day compliance period until Novembe
May 22, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 23, 2026
listing_status
Listing Status: GTBP — Normal (was Deficient)
GT Biopharma, Inc. - Common Stock | Nasdaq Financial Status Indicator D → N
Sep 15, 2026
trading_halt
Halt Resumed: GTBP — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-09-15T13:30:40.000Z | Resumed 2026-09-15T13:40:40.000Z
Sep 15, 2026
trading_halt
Trading Halt: GTBP — LUDP (Volatility Trading Pause)
GT Biopharma, Inc. Cm | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Sep 11, 2026
other
GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026
SAN FRANCISCO, CALIFORNIA, Sept. 11, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology comp
Sep 8, 2026
trading_halt
Halt Resumed: GTBP — trading resumed after T3 (News and Resumption Times)
Halted 2026-09-04T23:50:00.000Z | Resumed 2026-09-08T13:00:00.000Z
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-2.50 | $-2.50–$-2.50 | 87.9% | -25.0% | — | $0.0B | 1 |
| Next Q | $-2.50 | $-2.50–$-2.50 | 97.9% | -25.0% | — | $0.0B | 1 |
| Current FY | $-10.75 | $-10.75–$-10.75 | 93.6% | -26.5% | 1↑ 0↓ | $0.0B | 1 |
| Next FY | $-8.00 | $-8.00–$-8.00 | 25.6% | -18.5% | 1↑ 0↓ | $0.0B | 1 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-2.500 | — |
| 7d ago | $-2.000 | -0.500 |
| 30d ago | $-2.000 | -0.500 |
| 60d ago | $-2.000 | -0.500 |
| 90d ago | $-2.000 | -0.500 |
Institutional ownership
Which big funds own GTBP (from quarterly 13F filings) and who is adding or trimming.
24 institutional holders with $644.4K total value (1,422,096 shares) as of 2026-Q2. Top holders: JPMORGAN, VANGUARD, GEODE. Net buying activity: 4 institutions added/increased vs 2 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| JPMORGAN CHASE & CO | 1 | $0.00 | 0.0% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 376,399 | $184.4K | 28.6% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 266,788 | $130.6K | 20.3% | DOUBLED +1429.0% |
| VANGUARD FIDUCIARY TRUST CO | 225,938 | $110.7K | 17.2% | — |
| Arax Advisory Partners | 93,627 | $45.9K | 7.1% | — |
| NORTHERN TRUST CORP | 75,461 | $37.0K | 5.7% | — |
| Cetera Investment Advisers | 55,936 | $27.4K | 4.3% | — |
| PNC FINANCIAL SERVICES GROUP, INC. | 40,000 | $19.6K | 3.0% | — |
| OSAIC HOLDINGS, INC. | 38,500 | $18.9K | 2.9% | ADD +83.3% |
| LPL Financial LLC | 36,379 | $17.8K | 2.8% | DOUBLED +185.8% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| Integrated Wealth Concepts LLC | DOUBLED | 20,006 | 40,012 | +100.0% | $19.6K |
| OSAIC HOLDINGS, INC. | ADD | 21,000 | 38,500 | +83.3% | $18.9K |
| MORGAN STANLEY | ADD | 16,599 | 22,573 | +36.0% | $11.1K |
| ROYAL BANK OF CANADA | DOUBLED | 126 | 7,600 | +5931.7% | $4.0K |
| BNP PARIBAS FINANCIAL MARKETS | TRIM | 16 | 6 | -62.5% | $3.00 |
| UBS Group AG | NEAR_EXIT | 45,970 | 2 | -100.0% | $1.00 |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | 19,258 | 294,459 | +1429.0% | $120.2K |
| UBS Group AG | DOUBLED | 1 | 45,970 | +4596900.0% | $18.8K |
| LPL Financial LLC | DOUBLED | 10,632 | 30,382 | +185.8% | $12.4K |
| OSAIC HOLDINGS, INC. | DOUBLED | 2,000 | 21,000 | +950.0% | $8.6K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for GTBP.
Shares short
256,614
Settlement Sep 15, 2026
Change vs prior
-93.3%
Semi-monthly cycle
Days to cover
1.4
At avg daily volume
Of shares outstanding
≈14.2%
Estimate — not % of float
| Halted | Code | Reason | Status |
|---|---|---|---|
| Sep 15, 2026 | LUDP | Volatility Pause | Resumed |
| Sep 4, 2026 | T1 | News Pending | Not resumed |
| Sep 4, 2026 | T3 | Resumption Scheduled | Resumed |
All GTBP filing & press-release reports (7)
- 8-K reportSep 15, 2026
- 8-K reportSep 3, 2026
- PRESS-RELEASE reportAug 14, 2026
- 8-K reportMay 22, 2026
- S-1 reportApr 30, 2026
- 8-K reportApr 7, 2026
- PRESS-RELEASE reportMar 2, 2026